Investments and investor services
US benchmarks close higher as earnings season points to strong growth
US stocks advanced as traders remain bullish about the corporate earnings season
Company
Merck & Co Inc
NYSE:MRK
Merck & Co Inc is a global healthcare company. The company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products.
138 stories · page 5 of 7
US benchmarks pare gains in final minutes but close higher
A loom at the US and Canadian markets as the day progresses..
Merck & Co shares rise thanks to success of Phase 3 lung cancer trial
Patients treated with Keytruda lived significantly longer than those who received chemotherapy
Leucadia National, Merck & Co, Franklin Resources, Menlo Therapeutics - PRE-MARKET
Proactive takes a look at some movers and shakers before the bell on Monday April 9
Cidara soars in pre-market as lead antifungal drug breezes through mid-stage trial
Rezafungin was safe and well tolerated in patients with candidemia and/ or invasive candidiasis, while the data also showed evidence of the drug’s efficacy
MARKET MOVERS: DBV Technologies, InspireMD, Tetraphase...
There were a few mid- and late-stage trial failures which weighed on some pharma stocks on Wednesday...
Merck & Co's quarterly loss widens as it takes US$2.6bn hit due to US tax changes
Fourth quarter earnings beat forecasts but revenues missed
Merck shares continue to rise after successful lung cancer trial
Results from a large-scale trial showed a combination of Merck’s Keytruda drug and an older type of chemotherapy helped newly-diagnosed cancer patients live longer and stop the disease from advancing
Wall Street shares take a bath, but TSX up
Wall Street shares went lower on Monday as the shine came off the rally last week
Builders and building materials
Lennar Corp, CalAtlantic Group, Merck & Co, Enzymotec - AFTER HOURS
A look at what's happening before the bell in new York
Nasdaq Composite and S&P 500 storm to new highs, driven by tech stocks
The Nasdaq missed out on yesterday's advance but made up for lost time today
Merck shares slip premarket after hiking outlook following mixed bag of third quarter results
For the full year 2017, the drug giant raised its adjusted EPS outlook to US$3.91 to US$3.97 from US$3.76 to US$3.88 and lifted its revenue outlook to US$40.0bn to US$40.5bn from US$39.4bn to US$40.4bn
Archive
Lloyds Banking looking to put its trials behind it
PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
Lloyds, Barclays and RBS under the microscope with release of third quarter earnings
The week ahead includes third quarter earnings from Lloyds, Barclays and RBS along with trading updates from Shire, IAG and GSK
Merck discontinues one of its hepatitis C virus drug development programs
This decision was made based on a review of available Phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection
Celgene says US FDA places holds on clinical trials for cancer checkpoint inhibitor being developed with AstraZeneca
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
German drug giant Merck KGaA considering sale of US$1bn consumer health unit to meet financial targets
The consumer business -- whose brands include nutritional supplements Seven Seas and Bion and decongestant Nasivin – has been seen as lacking critical scale by analysts for a number of years.
AstraZeneca ovarian cancer drug approved for wider use
Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy
Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca
Merck & Co is yet to determine the full impact of the ‘Petya’ cyber attack in June that disrupted operations
Oil giants Exxon and Chevron find market hard to please - PRE-MARKET
Also featured: American Airlines and Merc & Co Inc